232 related articles for article (PubMed ID: 33057009)
1. An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics.
Hoang PH; Cornish AJ; Sherborne AL; Chubb D; Kimber S; Jackson G; Morgan GJ; Cook G; Kinnersley B; Kaiser M; Houlston RS
Blood Cancer J; 2020 Oct; 10(10):101. PubMed ID: 33057009
[TBL] [Abstract][Full Text] [Related]
2. Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort.
Kanamori T; Sanada M; Ri M; Ueno H; Nishijima D; Yasuda T; Tachita T; Narita T; Kusumoto S; Inagaki A; Ishihara R; Murakami Y; Kobayashi N; Shiozawa Y; Yoshida K; Nakagawa MM; Nannya Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Horibe K; Handa H; Ogawa S; Iida S
Br J Haematol; 2020 Dec; 191(5):755-763. PubMed ID: 32386081
[TBL] [Abstract][Full Text] [Related]
3. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Leleu X; Karlin L; Macro M; Hulin C; Garderet L; Roussel M; Arnulf B; Pegourie B; Kolb B; Stoppa AM; Brechiniac S; Marit G; Thielemans B; Onraed B; Mathiot C; Banos A; Lacotte L; Tiab M; Dib M; Fuzibet JG; Petillon MO; Rodon P; Wetterwald M; Royer B; Legros L; Benboubker L; Decaux O; Escoffre-Barbe M; Caillot D; Fermand JP; Moreau P; Attal M; Avet-Loiseau H; Facon T;
Blood; 2015 Feb; 125(9):1411-7. PubMed ID: 25575538
[TBL] [Abstract][Full Text] [Related]
4. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India.
Govindasamy P; Pandurangan P; Tarigopula A; Mani R; R Samuel C
Asian Pac J Cancer Prev; 2019 Jan; 20(1):235-241. PubMed ID: 30678438
[TBL] [Abstract][Full Text] [Related]
6. Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
Sawyer JR; Tian E; Heuck CJ; Epstein J; Johann DJ; Swanson CM; Lukacs JL; Johnson M; Binz R; Boast A; Sammartino G; Usmani S; Zangari M; Waheed S; van Rhee F; Barlogie B
Blood; 2014 Apr; 123(16):2504-12. PubMed ID: 24497533
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.
Chng WJ; Santana-Dávila R; Van Wier SA; Ahmann GJ; Jalal SM; Bergsagel PL; Chesi M; Trendle MC; Jacobus S; Blood E; Oken MM; Henderson K; Kyle RA; Gertz MA; Lacy MQ; Dispenzieri A; Greipp PR; Fonseca R
Leukemia; 2006 May; 20(5):807-13. PubMed ID: 16511510
[TBL] [Abstract][Full Text] [Related]
8. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
Walker BA; Wardell CP; Murison A; Boyle EM; Begum DB; Dahir NM; Proszek PZ; Melchor L; Pawlyn C; Kaiser MF; Johnson DC; Qiang YW; Jones JR; Cairns DA; Gregory WM; Owen RG; Cook G; Drayson MT; Jackson GH; Davies FE; Morgan GJ
Nat Commun; 2015 Apr; 6():6997. PubMed ID: 25904160
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma clonal evolution in homogeneously treated patients.
Corre J; Cleynen A; Robiou du Pont S; Buisson L; Bolli N; Attal M; Munshi N; Avet-Loiseau H
Leukemia; 2018 Dec; 32(12):2636-2647. PubMed ID: 29895955
[TBL] [Abstract][Full Text] [Related]
10. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Royle KL; O'Connor S; Cairns DA; Ashcroft AJ; Williams CD; Hockaday A; Cavenagh JD; Snowden JA; Ademokun D; Tholouli E; Andrews VE; Jenner M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Drayson MT; Brown JM; Morris TCM;
Br J Haematol; 2019 May; 185(3):450-467. PubMed ID: 30729512
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
12. Jumping translocations and high-risk myeloma.
Morgan GJ
Blood; 2014 Apr; 123(16):2442-3. PubMed ID: 24744247
[No Abstract] [Full Text] [Related]
13. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.
Avet-Loiseau H; Gerson F; Magrangeas F; Minvielle S; Harousseau JL; Bataille R;
Blood; 2001 Nov; 98(10):3082-6. PubMed ID: 11698294
[TBL] [Abstract][Full Text] [Related]
14. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
[TBL] [Abstract][Full Text] [Related]
15. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
[TBL] [Abstract][Full Text] [Related]
16. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.
Drach J; Ackermann J; Fritz E; Krömer E; Schuster R; Gisslinger H; DeSantis M; Zojer N; Fiegl M; Roka S; Schuster J; Heinz R; Ludwig H; Huber H
Blood; 1998 Aug; 92(3):802-9. PubMed ID: 9680348
[TBL] [Abstract][Full Text] [Related]
17. Chromosome microarray characterisation of chromosome arm 12p loss associated with complex molecular karyotype and recurrent adverse cytogenetic markers in multiple myeloma.
Hung D; Lenton D; Eslick R; Blennerhassett R; Joshi M; McCaughan G; Day S; Wright D
Genes Chromosomes Cancer; 2021 Oct; 60(10):668-677. PubMed ID: 34041820
[TBL] [Abstract][Full Text] [Related]
18. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.
Chang H; Li D; Zhuang L; Nie E; Bouman D; Stewart AK; Chun K
Leuk Lymphoma; 2004 May; 45(5):965-9. PubMed ID: 15291356
[TBL] [Abstract][Full Text] [Related]
19. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
Thakurta A; Ortiz M; Blecua P; Towfic F; Corre J; Serbina NV; Flynt E; Yu Z; Yang Z; Palumbo A; Dimopoulos MA; Gutierrez NC; Goldschmidt H; Sonneveld P; Avet-Loiseau H
Blood; 2019 Mar; 133(11):1217-1221. PubMed ID: 30692124
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal fluorescence
Merz M; Jauch A; Hielscher T; Mai EK; Seckinger A; Hose D; Bertsch U; Neben K; Raab MS; Salwender H; Blau IW; Lindemann HW; Schmidt-Wolf I; Scheid C; Haenel M; Weisel K; Goldschmidt H; Hillengass J
Haematologica; 2017 Aug; 102(8):1432-1438. PubMed ID: 28495913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
